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 Synopsis 
Objectives: Pathological disorder can disrupt the barrier integrity of the 
skin thereby altering the drug delivery from topical formulations to the 
target site. Cutaneous leishmaniasis is an infection of the dermal layers 
of the skin, and manifests as a variety of skin lesions from defined 
nodular forms to plaques and chronic ulcers. The aim of this work was to 
characterise the physiology and barrier integrity of the Leishmania-
infected BALB/c mouse skin and how they impacted delivery of drugs to 
the skin.  
Methods: A histological evaluation of the structural differences between 
uninfected and infected skin was performed using an H&E, elastic Von 
Gieson and IBA-1 stain. As a CL nodule developed and progressed, the 
skin pH, hydration and transepidermal water loss were recorded. Finally, 
Franz diffusion cells were used to evaluate the influence of the infection 
on drug delivery through the skin.  
Results: We found (i) structural changes in both the epidermal and 
dermal layers due to the ingress of inflammatory cells as shown by 
immunohistochemistry, (ii) a significant increase in trans-epidermal 
water loss (TEWL) and (iii) a significantly higher permeation of model 
permeants, caffeine and ibuprofen and the anti-leishmanial drugs 
buparvaquone and paromomycin, for Leishmania-infected skin compared 
to uninfected skin. The infection had no measurable influence on skin pH 
and hydration.  
Conclusions: we report profound changes in the skin barrier physiology, 
function and permeability to drugs of Leishmania-infected skin. 
 Introduction 
Cutaneous leishmaniasis (CL) is a parasitic disease that mainly affects 
poor communities in low- and middle-income countries with 
approximately 10 million people affected. 1 CL is characterized by a 
variety of clinical symptoms ranging from defined nodular forms to 
chronic ulcerative lesions. Non-complicated lesions tend to heal 
spontaneously, a process that can take 3 to 18 months depending on the 
Leishmania species and host susceptibility factors, and nearly always 
leave a disfiguring scar. 2 Available treatments such as miltefosine, 
amphotericin B and pentavalent antimonials are constrained by long 
treatment courses, parenteral drug administration, toxicity, cost and 
variable efficacy.  
In CL, Leishmania parasites typically reside in macrophages in the 
dermal layer of the skin. Although most current treatments for 
leishmaniasis are administered by other routes, for simple CL infected 
tissue can potentially be reached by topically applied drugs. Topical 
application is advantageous as it allows local and targeted drug exposure, 
thereby reducing the potential side effects and the need to carefully 
monitor the patient when given systemic treatment. Moreover, the ease 
of application makes it patient-friendly. Several topical formulations 
have been developed in the past to the point of clinical trials and used to 
treat CL infections, for example, the aminoglycoside paromomycin 
sulphate (WR279,397, 3 another paromomycin formulation Leshcutan® 
(Teva, Israel), and amphotericin B. 4 None of these proved to be entirely 
satisfactory due to side effects or lack of efficacy. For example local side 
 effects such as burning and irritation of the skin were commonly reported 
upon application of Leshcutan®. 5, 6 This is due to the presence of 12% 
methylbenzethonium chloride, a cationic quaternary ammonium 
compound that facilitates drug permeation into the skin. 7, 8  
The success of a topical formulation to treat CL depends on the anti-
leishmanial potency of the active ingredient and the amount of drug that 
reaches the parasites. 9 Skin disorders can alter barrier integrity resulting 
in increased or decreased drug delivery from topical formulations to their 
target site in the skin. 10-12 So far, drug delivery to diseased skin has 
mainly focused on non-infectious diseases, for example, psoriasis. In 
psoriatic plaques a reduced barrier integrity resulted in increased drug 
permeation compared to healthy skin. 13, 14 Infectious skin diseases 
caused by pathogens such as herpes, Tinea and Candida albicans have 
also been found to disrupt the physiology and barrier function of the 
skin. The barrier integrity in tinea-affected skin, was characterised by 
reduced stratum corneum hydration, enhanced proliferation and disturbed 
differentiation of the epidermis compared to healthy skin. 11  
To date there is no information available on the permeability of 
Leishmania-infected skin. An understanding of the permeability of skin 
infected by Leishmania parasites will help the optimisation of drug 
delivery. Thus, we aimed to characterise the skin barrier function in the 
early stages of CL in a mouse model with respect to histology, trans-
epidermal water loss (TEWL), skin pH, and the permeability to topically 
applied compounds. Caffeine and ibuprofen, two model permeants 15, 16 
were chosen for study because of their divergent physico-chemical 
 properties. Paromomycin sulphate was selected because it is the only 
currently available topical drug for CL while amphotericin B and 
buparvaquone were selected as attempts to reformulate these molecules 
17 (http://www.dndi.org/diseases-projects/portfolio/anfoleish-cl.html, 
accessed 3-06-2015) into topical formulations have been reported.  
 
Material and Methods 
Parasite strain and animals 
Leishmania major (MHOM/SA/85/JISH118) promastigotes were 
maintained in Schneider’s insect medium (Sigma Aldrich, UK) 
supplemented with 10% heat-inactivated foetal calf serum (Harlan, UK) 
at 26°C. The parasites were routinely passaged through BALB/c mice 
and low passage number promastigotes (typically below passage number 
3) were used for infection. Female BALB/c mice of about 6-8 weeks old, 
were purchased from Charles River (Margate, UK) and housed in a 
controlled environment of 55% relative humidity and 26°C. They were 
provided with tap water and a standard laboratory diet ad libitum. All in 
vivo experiments were carried out under license (PPL 70/6997) at the 
London School of Hygiene & Tropical Medicine (LSHTM) after 
discussion with the veterinarian, clearance through the LSHTM research 
ethics committee and according to UK Home Office regulations. 
In vivo CL model 
Five female BALB/c mice (6-8 weeks old; Charles River Ltd., UK) were 
shaved and injected the following day with 2x107 stationary phase L. 
 major JISH118 promastigotes (200 µL) subcutaneously on the rump 
above the tail. Three control mice were injected with medium that did 
not contain parasites.  
After about 7 days, a small papule at the site of injection was visible in 
the infected mice. The lesion size was measured daily using callipers. 
TEWL, skin pH and hydration were measured every other day as 
follows: mice were left to acclimatise in the room for 1 hour before being 
placed in the induction chamber. Anaesthesia were induced at 3% 
isoflurane with 100% oxygen at a flow rate of 2.5 L/min until no 
movement was observed and maintained with 2% isoflurane and 100% 
oxygen at 2.5 L/min. TEWL was measured using the Aquaflux AF102 
(Biox, London), the equipment was calibrated according to the 
manufacturer’s guidelines prior to starting the experiment and was 
baseline calibrated prior to use each day. Skin hydration was measured 
using the moisture checker (MY-808S, Scalar, Japan) and the skin-pH 
was obtained with the Skin-pH-Meter® PH 905 from CK electronics 
(Köln, Germany). The mice recovered from anaesthetics on a warm plate 
(37˚C). Statistical analysis were performed using SPSS software version 
19.0.  
When the lesion diameter reached 5-6 mm, the mice were sacrificed and 
the papule was excised for histological examination or permeation 
studies. For histological evaluation, the samples were collected and fixed 
in 10% neutral formalin solutions until they were further processed at the 
UCL Institute of Neurology (Queen Square, London). Images of the 
processed and stained samples were taken using a Leica DMRB 
 microscope (Leica, Germany) equipped with a Leica DFC 420 camera 
controlled by Leica Application Suite (version 3.1). For permeation 
studies, the uninfected control tissue was taken from above the CL 
nodule on the back of the same donor mouse.  
 
 Investigation into permeability of infected vs uninfected skin 
Franz cell devices with narrow diameter (5 mm) were produced (Soham 
Scientific, Fordham, UK) in order to measure the permeation of a drug 
through a Leishmania infected skin area (5 mm diameter). All drugs were 
purchased from Sigma Aldrich (Dorset, UK) except for amphotericin B, 
which was obtained from VWR International (Leicestershire, UK) and 
[3H]-paromomycin sulphate (specific activity: 0.2 Ci/mmol, 
radiochemical purity: 99.8% and radioactive concentration: 500 µCi/mL) 
was obtained from Moravek Biochemicals (Brea, CA). Saturated donor 
solutions for caffeine, ibuprofen, paromomycin sulphate and 
buparvaquone were prepared by adding an excess amount of drug to PBS 
(Sigma Aldrich) and leaving it to stir at 32 ˚C for 48 hours prior to the 
experiment. The paromomycin sulphate drug suspension was centrifuged 
at 13000rpm for 30 minutes and the supernatant was removed and spiked 
with 10 µCi of [3H]-paromomycin sulfate per Franz diffusion cell. The 
amphotericin B donor solution was prepared by adding an excess amount 
of drug to PBS followed by 1 hour of sonication.  
The full-thickness skin pieces were inspected for macroscopic damage 
and muscle and fat tissue were carefully removed using forceps. Skin 
pieces were cut in circular discs of about 2cm diameter. They were then 
 mounted between the donor and receptor compartment of the Franz cell 
device and kept in place by a clamp. The receptor fluid consisted of a 
PBS solution that was sonicated for 30 minutes to remove air bubbles 
prior to adding it to the Franz cell device. For the permeation of the more 
lipophilic compounds, buparvaquone and amphotericin B, PBS was 
supplemented with 2% hydroxypropyl-β-cyclodextrin (Sigma Aldrich) 17 
(CD) in order to ensure sink conditions during the experiment. A small 
magnetic stirrer was introduced through the sampling arm, taking care 
not to introduce bubbles. Prior to applying the donor solution, the cells 
were incubated in a warm water bath. After 1 hour, each cell was 
checked for leakage and the presence of air bubbles. 250 µL of the donor 
solution was applied to each donor compartment. Receptor fluid samples 
were taken at regular time intervals and analyzed by HPLC-UV or by 
liquid scintillation counting for paromomycin sulphate. Flux and lag time 
were calculated using the linear portion of the graph when the 
cumulative amount of drug permeated was plotted as a function of time. 
Statistical analysis were performed using SPSS software version 19.0. 
The permeability coefficient was calculated according to the following 
equation: 
 
Whereby J is the flux of the permeant per unit area (in mol·cm-2·s-1) and 
C0 is the concentration of drug applied to the skin surface (in mol·cm-3). 
The saturated drug concentration was determined by adding an excess 
amount of drug to PBS in a clean vial. A magnetic stirrer was added and 
the suspension was left to stir for 48 hours at 32 ˚C. An aliquot of the 
J =KpC0
 suspension was centrifuged at 13000 rpm at 32 ˚C for 30 minutes. The 
supernatant was taken and analysed by HPLC-UV. 
Drug quantification 
HPLC-UV. All compounds, except paromomycin, were analysed using a 
1260 Infinity Agilent HPLC system. The column and settings used to 
separate and detect the compounds are summarised in Table 1. 
Liquid scintillation counting. Because paromomycin sulfate lacks 
ultraviolet absorbing chromophore functions HPLC-UV could not be 
used to analyse the permeation samples. Therefore the donor solution 
was spiked with radiolabeled paromomycin sulfate and permeation 
samples were analysed using liquid scintillation counting. Thus 100 µL 
of receptor fluid and 100 µL of Optiphase™ supermix cocktail (Perkin 
Elmer, Buckinghamshire, UK) were added to a 96-well flexible PET 
microplate (Perkin Elmer, Buckinghamshire, UK). The plates were 
incubated on a plate shaker for 1 hour at room temperature after which 
they were fitted in an appropriate support cassette and placed in the 
MicroBeta® Trilux with two detectors for scintillation counting (1 
minute/well).  
Each plate included 3 blanks containing PBS that had been in contact 
with mouse skin (100 µL of PBS), 3 negative controls (100 µL of 
paromomycin sulfate saturated solution without radiolabeled compound) 
and 12 standards (1/5 dilutions). Additionally 3 samples of the donor 
solution were analysed to confirm homogeneous distribution of the 
radiolabeled compound in the solution. The counts per minute readings 
 obtained for the samples were converted to mg of paromomycin 
sulfate/ml using the standard curve. 
Results  
Histological changes in Leishmania-infected skin 
A histological examination of the epidermal and dermal layers indicated 
structural skin changes upon infection with Leishmania parasites, as 
shown in Figures 1 and 2. The following changes to infected skin were 
observed: (i) an upward movement of the skin layers due to the 
infiltration of cells, with a disruption of the continuity of the epidermal 
and dermal skin layers at the centre of the lesion (Figure 1 (C)), (ii) an 
increased number of epidermal cell layers compared to uninfected skin 
(Figures 1 (B) and (D)) suggesting epidermal hyperplasia, (iii) abundant 
presence of macrophage-like cells in the dermal and lower epidermal 
layers (Figure 2 (B)), (iv) and collagen fibres were more spread out and 
less dense in infected skin (Figure 2 (D)), compared to the dense network 
of fibres in uninfected skin (Figure 2 (C)). 
 
Transepidermal water loss (TEWL), skin hydration and pH 
of Leishmania-infected mouse skin 
Changes in TEWL of infected and uninfected mouse skin with time are 
shown in Figure 3. Baseline TEWL values (prior to infection) in both 
groups were similar (t-test; p>0.05) indicating no difference in the 
‘inside-outside’ skin barrier function between the groups. TEWL values 
increased slightly in both groups on day 2 potentially due to temporary 
 skin damage caused by the needle insertion. By day 10, when the 
infected mice had developed a nodule with a diameter of 5.4±0.7 mm, 
the mean TEWL values in the infected group had increased significantly 
compared to the uninfected group (t-test, p<0.05).  
There were no significant differences in skin pH and hydration recorded 
over time (repeated measures ANOVA, p >0.05) with average values of 
pH 5.8±0.3 and 5.6%±0.6 hydration and pH 5.8±0.3 and 6.0%±0.5 
hydration in infected and uninfected mice respectively.  
Ex vivo permeability of Leishmania-infected skin 
The cumulative amount of each test molecule in the receptor 
compartment of Franz diffusion cells, as a function of time, is shown in 
Figure 4 and permeation derived parameters such as lag time, flux and 
permeability coefficients are shown in Table 2.  
Infected skin was more permeable to the model molecules compared to 
uninfected skin. Both caffeine and ibuprofen, applied as a saturated 
solutions, showed a higher permeation through infected skin compared to 
uninfected skin. At the end of the 48-hour experiment, the cumulative 
amount of caffeine that had permeated through infected skin was 2 to 47 
times higher compared to uninfected skin (t-test, p < 0.05), the flux was 
66 times higher and the permeability coefficient was 50 times higher for 
infected skin compared to uninfected skin (p<0.05). For ibuprofen, the 
corresponding differences between infected and uninfected skin were 
more modest, although they were still statistically significant. After 48 
hours of permeation, the cumulative amount of permeated ibuprofen was 
2 to 3 times higher while the flux and permeability coefficient were twice 
 as high for the infected skin compared to the uninfected skin (t-test, 
p<0.05). Interestingly, for both caffeine and ibuprofen, there was no 
difference in lag times for infected an uninfected skin (t-test, p >0.05).  
For the anti-leishmanial drugs, uninfected skin was impermeable to the 
test compounds and no drugs could be detected in the receptor phase 
throughout the 48-hour permeation experiment. In contrast, the 
permeability of infected skin depended on the drug, being impermeable 
to amphotericin B, slightly permeable to buparvaquone, and highly 
permeable to paromomycin.  
When the permeation profiles and parameters of all the tested 
compounds through infected skin are compared, paromomycin sulphate 
had the highest flux compared to caffeine, ibuprofen and buparvaquone 
(one-way ANOVA, p<0.05) while buparvaquone had the highest lag 
time and permeability coefficient compared to paromomycin, caffeine 
and ibuprofen (p >0.05 for both lag time and Kp). 
 
Discussion  
A number of approaches were used to characterise skin barrier integrity, 
an important parameter that influences topical drug delivery to 
Leishmania-infected skin. We first examined the histopathological 
changes in skin physiology. The most outstanding observation was the 
ingress of abundant inflammatory cells to the place of infection which 
disturbed the continuity of the epidermal and dermal skin layers. This is 
similar to previous reports of inflammation in BALB/c mice that are 
 highly susceptible to Leishmania major infection, and where lesions are 
characterised by extensive inflammation, ulceration and necrosis. 18-21 
The disturbance to the epidermal and dermal skin layers, shown by the 
reduced density of the collagen and epidermal hyperplasia, indicates that 
the skin barrier properties may be reduced; abnormalities in the 
epidermal layer such as proliferation and differentiation being known to 
be essential for the integrity of the skin barrier function. 22 Indeed, 
reduced skin barrier properties were observed. TEWL – an indication of 
how well the skin controls water movement from the interior of the body 
– was doubled in Leishmania-infected skin. Such increase in TEWL was 
also observed in a number of other skin diseases such as tinea infections, 
psoriasis. 11, 23, 24  
Interestingly, the skin hydration, measured by the moisture sensor, did 
not change upon infection. This was surprising as inflammation in the 
infected lesion and the subsequent oedema was expected to increase the 
water content in the skin. Our results may be explained by the fact that 
the moisture sensor only measures the moisture content of the stratum 
corneum, 25 and not that of the whole skin. It appears that despite fluid 
accumulation in the Leishmania lesion, the surface of the skin does not 
become more hydrated compared to uninfected skin.  
Uninfected mouse skin had an acidic surface, correlating with the “acid 
mantle” term used to describe the inherent acidic nature of the stratum 
corneum, 26 and the pH value of 5.8 is similar to previously reported 
value of 5.9 for hairless mouse skin. 27 Skin surface pH is known to be 
influenced by certain diseases, for example, tinea infection in humans 
 resulted in a higher foot skin pH. 28 The absence of any difference in the 
pH of Leishmania- infected and uninfected skin could be due to the fact 
that Leishmania infection was not located in the stratum corneum. 
Instead, as shown in Figure 2E, the L. major amastigotes were present in 
the dermis. 
The reduced barrier function of Leishmania-infected skin indicated by 
TEWL (as discussed above) was confirmed in permeation experiments. 
However, the permeant’s size and lipophilicity play a critical role in its 
permeation (or lack of). The hydrophilic molecules paromomycin 
sulphate and caffeine showed much larger increases in flux compared to 
the more lipophilic molecules ibuprofen and buparvaquone through 
infected skin. The presence of Leishmania parasites in the skin triggers a 
cascade of reactions resulting in inflammation and release of 
chemokines. 29, 30 It seems that the subsequent oedema, caused by 
additional fluid accumulating in the interstitial spaces, facilitates 
permeation of the more water soluble compounds such as caffeine and 
paromomycin sulphate while the permeation of drugs with low water 
solubility such as buparvaquone was not increased to the same extent. 
Another possible reason for the enhanced permeation of the water 
soluble compounds could be the greater concentration gradient from 
donor to receptor phases for compounds with a higher aqueous solubility. 
All the permeants were applied as saturated solutions and therefore had a 
thermodynamic activity of 1. The rate of diffusion of molecules through 
a membrane is proportional to the concentration gradient. For the highly 
-water soluble paromomycin sulfate, this gradient is nearly 25 times 
 higher compared to caffeine  and more than 4000 times higher compared 
to ibuprofen. This is likely to contribute to this increased permeation for 
more water soluble compounds.  
In contrast to paromomycin, buparvaquone’s flux through infected skin 
is hampered by its low water solubility and it’s high lipophilicity, as 
suggested for healthy skin. 17 Low water solubility means low drug 
concentration in the donor phase and hence low concentration gradient 
across the skin, while drugs with a high lipophilicity means that the drug 
is able to quickly partition into the lipid component of the stratum 
corneum and remains there preferentially, such that a very long lag time 
and low flux through the damaged infected skin is observed. 
As mentioned above, permeant size was also critical to its flux through 
infected skin. Amphotericin B with a molecular weight of 924 g/mol 
proved to be too large, as well as too water-insoluble, a molecule to 
permeate through uninfected or infected skin. This reflects previous in 
vitro 31, 32 and in vivo 33-35 studies and explains why previous studies in 
mice reported no cure of leishmaniasis lesions after topical application of 
amphotericin B (a potent anti-leishmanial drug), 36 despite its efficacy 
when administered through other routes, for example intradermally. 20  
In contrast to the mouse study by El-On et al (1984), one clinical study 
reported reduction in lesion size of cutaneous leishmaniasis lesions 
following the application of amphotericin B in solvents such as ethanol, 
34 this was possibly due to skin lipid removal by ethanol leading to 
reduced barrier function and a potential increase in drug permeation. In 
 another clinical study on ulcerated lesions, the topical application of the 
lipidic formulation Amphocil in 5% ethanol Vardy et al. (2001) reported 
a faster healing rate compared to placebo except for one lesion. 37 In this 
case, the major reason for lesion healing caused by amphotericin B 
would be the absence of the stratum corneum in CL ulcers, i.e the 
absence of any barrier to the topically-applied drug from its site of 
action.   
In addition, amphotericin B, paromomycin and buparvaquone were also 
unable to permeate through healthy uninfected skin. Paromomcyin also 
has a high molecular weight and physicochemical properties that are 
unfavourable for skin permeation. This was reflected in the lack of 
permeation through uninfected skin in our study, as described previously 
by Nogueira et al. (2009) who evaluated the permeation of different 
paromomycin salts through mouse skin. 38 In contrast the permeation of 
paromomycin through infected skin was expected as Aguiar et al. (2009)  
reported systemic absorption after topical application on ulcerated CL 
lesions in BALB/c mice39. It is important to note that the absence of the 
SC in such ulcerated lesions is likely to enhance the permeation into the 
dermis where the drug enters the blood circulation; this differs from the 
conditions in our experiment where the permeation through nodular CL 
lesions, with epidermis and SC, was evaluated.  
The inter-individual variability in our permeation profiles (Figure 4) was 
high. Similar variability, has been reported in previous clinical studies 40-
42 and was ascribed to differences in skin lipid composition and stratum 
corneum thickness between the test subjects. In this study inbred BALB/ 
 mice were used to mitigate inter-individual variability. However, 
possible changes caused experimental manipulations as suggested by 43, 
44 could not be avoided. Moreover, the permeation experiments which 
were conducted on infected skin, included variations in the progression 
of the infection in individual mice, despite the use of a standardised 
inoculum of L. major parasites to create lesions.   
Despite the variability, we found a greater permeability of Leishmania-
infected skin and the influence of the permeant’s molecular mass and 
water-solubility/hydrophilicity was established. The importance of this 
data in relation to treatment of clinical CL is at present unclear due to 
known differences in mouse and human skin, including (i) the thinner 
mouse skin and mouse stratum corneum, 45 (ii) the absence of sweat 
glands in mouse skin, and (iii) the higher number of hair follicles in 
mouse skin and (iv) the different composition of intercellular stratum 
corneum  lipids 46 which can all contribute to the higher permeability of 
mouse skin. 47-49 Further studies on human skin are required to determine 
whether these alterations in mouse skin are predictive of similar changes 
in human skin. This is important in relation to both the potential of new 
anti-leishmanial drugs in topical formulations, and an approach towards 
the direct administration of topical formulations on intact skin over CL 
nodules or around CL ulcers, where the infection is found in the dermis, 
which should avoid the need for removal of the ulcerative crust, washing 
and occlusion. 3 
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Table 1. Details of the HPLC methods for caffeine, ibuprofen, amphotericin 
B and buparvaquone. 
Compound ID HPLC column 
Injection 
volume  
(µl) 
Mobile phase Flow rate 
(ml/min) 
Detector 
wavelength 
(nm) A B 
Caffeine Phenomenex; Synergi–Hydro 
RP (250x4.6mm; 5µm) 
20 0.1% TFA in 
water (15%) 
ACN (85%) 1.3 273 
Ibuprofen Phenomenex; Synergi–Hydro 
RP (250x4.6mm; 5µm) 
20 0.1% TFA in 
water (30%) 
ACN (70%) 1 227 
Amphotericin 
B 
Phenomenex; Synergi–Hydro 
RP (250x4.6mm; 5µm) 
80 
2.5mM EDTA 
in water (68%) 
ACN (37%) 1 407 
Buparvaquone 
Luna C18 (4.6x250mm; 5µm) 
with Luna guard column 
20 
5% Water+ 
acetic acid 
(pH3.5) (5%) 
MeOH (95%) 1.7 250 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. The physico-chemical properties (solubility, log D and molecular 
weight) and permeation parameters (flux, lag time and permeability 
coefficient (Kp)) for the drugs tested (mean+/-SD, n=5). 
 caffeine ibuprofen 
paromomycin 
sulphate 
amphotericin 
B 
buparvaquone 
Solubility (mg/ml) 
PBS (pH 7.4) 
PBS+2%CD  
 
22.74±5.26 
 
 
0.15±0.01 
 
 
>650000 
N/A 
 
< 0.75 
37±4 
 
<0.1 
853±25 
Log D -0.07 (pH 3.0)1 4.02 -2.93 -0.663 7.0 (pH 3.0)4 
Mol. weight (g/mol) 194 206 714 924 326 
Flux (µg/cm2/h) 
uninfected 
infected 
 
0.6±0.1 
40.1±43.8 
 
7.3±1.2 
15.0±3.7 
 
Not detected 
548±201 
 
Not detected 
Not detected 
 
Not detected 
0.17±0.1 
Lag time (h) 
uninfected 
infected 
 
14.9±5.2 
12.7±3.5 
 
11.4±1.1 
10.7±0.5 
 
Not detected 
15.4±4.0 
 
Not detected 
Not detected 
 
Not detected 
25.32±3.1 
Kp (cm/h) 
uninfected 
infected 
 
2.3E-05±5.5E-06 
1.1E-03±8.5E-04 
 
0.05±0.01 
0.11±0.03 
 
Not detected 
7.01E-04 
 
Not detected 
Not detected 
 
Not detected 
1.75±1.0 
1 50 
2 51 
3 (estimated using ChemBioDraw Ultra 13.0) 
4 52 
 Figure 1. Histology sections of BALB/c mouse skin (H&E stain) showing the 
L. major skin on the rump in an infected and uninfected biopsy. (A and B) 
uninfected skin at day 11 after injection of medium without parasites, (B) is a 
magnification of the epidermis in uninfected skin indicated by the bracket; (C, D 
and E) infected skin at day 11 after infection, (D) is a magnification of the 
epidermis in infected skin indicated by the bracket (E) is a magnification of the 
lower dermal layer of infected skin and shows the presence of L. major 
amastigotes in the phagolysosomes of macrophages indicated by the circles. 
 
Figure 2. Histology sections of BALB/c mouse skin showing the L. major 
skin on the rump in an infected and uninfected biopsy. (A) Iba-1 stain of 
uninfected skin at day 11 after injection of medium without parasites, (B) Iba-1 
stain of infected skin at day 11 after infection. The abundant brown staining 
indicates infiltration of numerous macrophage-like cells in the dermis. (C) Von 
Gieson staining of uninfected skin on day 11. The collagen fibres present in the 
dermis are visualized by an intense red stain, (D) Von Gieson staining of 
infected skin on day 11 after infection. The staining is less intense and the fibres 
are spaced by invading inflammatory cells. Moreover the thickening of the 
epidermis, the outer layer of the skin, is clearly visible.  
 
Figure 3. TEWL and lesion size evolution in time in infected and uninfected 
skin (average±SD). TEWL values are significantly higher for the L. major 
infected skin (n=10) compared to the uninfected skin (n=6) on day 10 after 
infection, when a nodule size of 5-6mm diameter was reached (repeated-
measures ANOVA, p < 0.05; n=5 in each group). This indicates an impaired in 
to outside skin barrier.  
 
Figure 4.The cumulative amount of caffeine, ibuprofen, buparvaquone and 
paromomycin sulphate permeated per surface area (µg/cm2) through 
uninfected and infected skin as a function of time (h). The permeation 
profiles are of individual skin samples. Each mouse provided 2 skin samples, 
one infected (filled symbol) and one uninfected (unfilled symbol). 
